IDEXX will add canine mast cell tumor detection to its Cancer Dx™ Panel in North America beginning mid-2026. The expanded panel will screen for mast cell tumors and lymphoma, addressing over one-third of all canine cancer cases. More than 5,500 veterinary practices already use the lymphoma test, which can detect disease up to eight months before symptoms appear. Mast cell tumor testing will require no change to sample collection or workflow, deliver results within 2–3 days in the U.S. (2–4 days in Canada), and be offered at no extra cost. IDEXX projects that routine wellness visits for dogs aged seven years and older, and high-risk breeds aged four years and older, will incorporate this screening, potentially identifying hundreds of cases earlier each year and guiding more timely treatment decisions.

IDEXX began a controlled U.S. rollout of its inVue Dx™ Cellular Analyzer for fine-needle aspiration (FNA) cytology in late Q4 2025, initially focusing on mast cell tumors. The slide-free system enables veterinarians to evaluate skin masses, identify and quantify cells, and obtain results during the patient visit. Practices can also request remote expert review from IDEXX pathologists without preparing traditional slides. Over the course of 2026, the menu of in-clinic cytology applications will expand beyond mast cell tumors, broadening inVue Dx’s utility and reducing referral delays while improving diagnostic confidence in more than 6,000 anticipated installations by year-end.

In early 2026, IDEXX introduced the ImageVue™ DR50 Plus Digital Imaging System, delivering high-definition radiographs at up to 25% lower radiation dose than its predecessor and up to 60% less than competing solutions. The system’s advanced detector design and automated exposure protocols reduce retakes and streamline imaging workflows. A new 17" x 17" panel complements the existing 14" x 17" option, expanding coverage for larger patients. Integrated with IDEXX Web PACS™ software and Telemedicine Consultants, the solution cuts case-submission clicks by more than 45% and supports 24/7 specialist access across radiology and cardiology, enhancing diagnostic throughput in over 3,000 installations projected in its first year.

These diagnostic advances reinforce IDEXX’s position as a global leader in veterinary innovation. The company employs approximately 11,000 people and serves customers in over 175 countries. By broadening its cancer diagnostics portfolio and enhancing imaging capabilities, IDEXX aims to drive recurring revenue from reference laboratory services and in-clinic analyzers. Investors should note the mid-2026 timing for mast cell panel rollout and the phased expansion of inVue Dx cytology and ImageVue DR50 Plus availability across North America. As proactive screening and low-dose imaging become standard practice, IDEXX is positioned to capture incremental market share, support practice growth, and sustain long-term revenue expansion.